92 search results for: quality of life

expert video

Comorbidities and Disease Burden in CSU

10 min

Dermatology

In their interview Drs. Maurer and Ensina shed light on the significant burden of comorbidities in CSU.

expert video

Can Emerging Treatments Help Address Individual PN Patient Burden?

17 min

Dermatology

Prof. Sonja Ständer emphasizes the high patient burden of PN, and how this is influenced by patient needs and comorbidities. She discusses how emerging treatments are reducing patient burden.

expert video

Current Treatment Landscape and Emerging Therapies

16 min

Dermatology

Dr. Lawrence F. Eichenfield reviews the evolving therapeutic landscape for children with AD, considering clinically relevant data supporting the use of advanced systemic therapies. This video was recorded at the EADV 2023 annual meeting during the ‘New Horizons in Children With Atopic Dermatitis: Emerging Evidence in Disease Management’ presentation.

Impact <b>of</b> Type 2 Inflammation on Pediatric Atopic Dermatitis, Asthma and Eosinophilic Esophagitis

expert video

Impact of Type 2 Inflammation on Pediatric Atopic Dermatitis, Asthma and Eosinophilic Esophagitis

9 min

Type 2 Inflammation

Prof. Stephan Weidinger discusses the impact of type 2 inflammation on disease burden and clinical outcomes in pediatric patients.

The Evolving Understanding <b>of</b> Prurigo Nodularis (PN) Has Implications for Patient Management

Infographic

The Evolving Understanding of Prurigo Nodularis (PN) Has Implications for Patient Management

5 min

Dermatology

An infographic summarizing the clinical manifestations and pathophysiological processes of PN.

Why did the definition <b>of</b> control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

expert video

Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

5 min

Rhinology

Prof. Hellings and Prof. Corso discuss the significance and rationale behind the new definition of CRSwNP.

interactivity

Chronic Obstructive Pulmonary Disease: Disease Burden & Heterogeneity

5 min

Pulmonology

Learn about the disease burden and heterogeneity of chronic obstructive pulmonary disease (COPD).

expert video

Neuroiflammation and Neurogenic Itch in Prurigo Nodularis

2 min

Dermatology

Dr. Chovatiya discusses the neuroinflammatory mechanisms of PN.

The Disease Burden <b>of</b> AD in Children and the Impact <b>of</b> Type 2 Comorbidities

expert video

The Disease Burden of AD in Children and the Impact of Type 2 Comorbidities 

12 min

Dermatology

Multidimensional disease burden of atopic dermatitis in children from a real-world case study – Presentation from the ADVENT symposium at EAACI 2023.

expert video

ERS 2024 | A Breath of Fresh Air: A Greater Understanding of COPD With Type 2 Inflammation

45 min

Pulmonology

Professors Henrik Watz, Mona Bafadhel, and Alberto Papi discuss the pathophysiology of COPD with type 2 inflammation and review current and emerging biologic therapies

Tools for Clinical Assessment <b>of</b> Prurigo Nodularis

Infographic

Tools for Clinical Assessment of Prurigo Nodularis

17 min

Dermatology

An interactive guide that provides users with an overview of key assessment tools for Prurigo Nodularis clinical practice. Implementation of the most applied tools is exemplified via a patient case.

Podcast

ADVENT On Air | Loss of Smell in CRSwNP Patients

15 min

Rhinology

Profs. Wytske Fokkens and Joaquim Mullol discuss the clinical significance of the loss of smell in patients with CRSwNP.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: SudanChange country/region